TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Personalized Mobility Interventions Using Smart Sensor Resources for Lower-Limb Prosthesis Users
Brief Summary: The goal of this research is to analyze data from smartphone-based and wearable sensors, using advanced machine-learning and data-mining techniques, and to combine this information with performance-based measures, participant-reported measures, and structured interviews to create a clinical toolbox to (i) identify individuals who exhibit reduced prosthesis use (compared to expected usage levels based on K-level designation and/or participant goals of community mobility and social interaction), (ii) identify prosthetic/physical and psychological factors that limit prosthesis use, and (iii) determine the effect of targeted interventions to increase prosthesis use and facilitate achievement of participant goals. Objective sensor-based measurement of home and community activities will allow for the correlation of real-world function to in-clinic assessments and to monitor changes resulting from rehabilitation interventions in real time. Machine-learning and data mining techniques will be used to identify a subset of measures from this toolbox that sensitively and accurately reflect real-world function, enabling clinicians to predict and assess activity and provide effective interventions to optimize prosthesis use. The goal of this project, to improve overall performance with respect to activities of daily living and other real-world activities, thus addresses the Fiscal Year 2017 (FY17) Orthotics and Prosthetics Outcomes Research Program (OPORP) Focus Area of Orthotic or Prosthetic Device Function.


Options:
A: Arm Label: Early PABC Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Behavior Change (PABC) | Arm Label: Wait-List Control Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Activity Behavior Change (PABC) | Intervention Type: BEHAVIORAL; Name: Physical Activity Behavior Change (PABC); Assigned to Arm(s): Early PABC Intervention, Wait-List Control Intervention | Intervention Type: BEHAVIORAL; Name: Physical Activity Behavior Change (PABC); Assigned to Arm(s): Early PABC Intervention, Wait-List Control Intervention
B: Arm Label: EBAR Program; Type: EXPERIMENTAL; Interventions: Other: EBAR Program | Arm Label: Wait List Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: EBAR Program; Assigned to Arm(s): EBAR Program
C: Arm Label: Not Meeting Mobility Goals; Type: EXPERIMENTAL; Interventions: Other: Needs-based intervention (physical, psychological, or both) | Intervention Type: OTHER; Name: Needs-based intervention (physical, psychological, or both); Assigned to Arm(s): Not Meeting Mobility Goals
D: Arm Label: SMART & Peer Support; Type: EXPERIMENTAL; Interventions: Device: Self-Management for Amputee Rehabilitation using Technology [SMART] | Intervention Type: DEVICE; Name: Self-Management for Amputee Rehabilitation using Technology [SMART]; Assigned to Arm(s): SMART & Peer Support

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adapting and Expanding the Algorithmic Software Tool to Help Manage Asthma (ASTHMAXcel) for Youth With Asthma
Brief Summary: This project seeks to test and refine an adapted/expanded version of a previously created ASTHMAXcel app.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Tailored Web-based Asthma Management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Generic web-based asthma education | Intervention Type: BEHAVIORAL; Name: Tailored Web-based Asthma Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Generic web-based asthma education; Assigned to Arm(s): 2
B: Arm Label: CHESS + Case Mgt; Type: EXPERIMENTAL; Interventions: Behavioral: CHESS Internet telehealth | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHESS Internet telehealth; Assigned to Arm(s): CHESS + Case Mgt
C: Arm Label: Reference; Type: OTHER; Interventions: Behavioral: Marketed experience application on adherence | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Marketed experience application on adherence | Intervention Type: BEHAVIORAL; Name: Marketed experience application on adherence; Assigned to Arm(s): Intervention, Reference
D: Arm Label: Intervention Arm; Type: EXPERIMENTAL; Interventions: Other: ASTHMAXcel App | Arm Label: Usual Care Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: ASTHMAXcel App; Assigned to Arm(s): Intervention Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Implementing, Evaluating, and Scaling Up of the Strengthening a Palliative Approach in Long Term Care (SPA-LTC) Program
Brief Summary: This study will evaluate the implementation of the Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) program using a cross-jurisdictional, effectiveness-implementation type II hybrid design (dual testing of clinical and implementation interventions) to assess the implementation (feasibility, fidelity, reach, sustainability) and effectiveness (family satisfaction, staff knowledge and confidence implementing a palliative approach to care, hospital use).


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Strengthening a Palliative Approach in Long-Term Care (SPA-LTC) Program; Assigned to Arm(s): Intervention
B: Arm Label: Intervention group; Type: OTHER; Interventions: Other: MultiDisciplinary Team Meetings (MDTM) | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MultiDisciplinary Team Meetings (MDTM); Assigned to Arm(s): Intervention group
C: Arm Label: INH (Intervention Nursing Homes); Type: EXPERIMENTAL; Interventions: Other: TIME | Arm Label: CNH (Control Nursing Homes); Type: ACTIVE_COMPARATOR; Interventions: Other: Education-only intervention | Intervention Type: OTHER; Name: TIME; Assigned to Arm(s): INH (Intervention Nursing Homes) | Intervention Type: OTHER; Name: Education-only intervention; Assigned to Arm(s): CNH (Control Nursing Homes)
D: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: ACP+ programme | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACP+ programme; Assigned to Arm(s): Intervention group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Replication of Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS Trial)
Brief Summary: Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.


Options:
A: Arm Label: Clopidogrel 75 mg; Type: N/A; Interventions: Drug: Clopidogrel 75mg | Arm Label: Ticagrelor 90 mg; Type: N/A; Interventions: Drug: Ticagrelor 90mg | Intervention Type: DRUG; Name: Ticagrelor 90mg; Assigned to Arm(s): Ticagrelor 90 mg | Intervention Type: DRUG; Name: Clopidogrel 75mg; Assigned to Arm(s): Clopidogrel 75 mg
B: Arm Label: DPP4i; Type: N/A; Interventions: Drug: DPP-4 inhibitor | Arm Label: Empagliflozin; Type: N/A; Interventions: Drug: Empagliflozin | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: DPP-4 inhibitor; Assigned to Arm(s): DPP4i
C: Arm Label: DPP4i; Type: N/A; Interventions: Drug: DPP-4 inhibitor | Arm Label: Canagliflozin; Type: N/A; Interventions: Drug: Canagliflozin | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin | Intervention Type: DRUG; Name: DPP-4 inhibitor; Assigned to Arm(s): DPP4i
D: Arm Label: 2nd generation sulfonylureas; Type: N/A; Interventions: Drug: Sulfonylurea | Arm Label: Linagliptin; Type: N/A; Interventions: Drug: Linagliptin | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): 2nd generation sulfonylureas

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims
Brief Summary: Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.


Options:
A: Arm Label: Clopidogrel 75 mg; Type: N/A; Interventions: Drug: Clopidogrel 75mg | Arm Label: Prasugrel 10 mg; Type: N/A; Interventions: Drug: Prasugrel 10mg | Intervention Type: DRUG; Name: Prasugrel 10mg; Assigned to Arm(s): Prasugrel 10 mg | Intervention Type: DRUG; Name: Clopidogrel 75mg; Assigned to Arm(s): Clopidogrel 75 mg
B: Arm Label: Linagliptin; Type: N/A; Interventions: N/A | Arm Label: Glimepiride; Type: N/A; Interventions: N/A
C: Arm Label: 2nd generation sulfonylureas; Type: N/A; Interventions: Drug: Sulfonylurea | Arm Label: Linagliptin; Type: N/A; Interventions: Drug: Linagliptin | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): 2nd generation sulfonylureas
D: Arm Label: 2nd Generation SUs; Type: N/A; Interventions: Drug: Sulfonylurea | Arm Label: Saxagliptin; Type: N/A; Interventions: Drug: Saxagliptin | Intervention Type: DRUG; Name: Saxagliptin; Assigned to Arm(s): Saxagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): 2nd Generation SUs

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Replication of the CARMELINA Diabetes Trial in Healthcare Claims
Brief Summary: Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.


Options:
A: Arm Label: 2nd Generation SUs; Type: N/A; Interventions: Drug: Sulfonylurea | Arm Label: Sitagliptin; Type: N/A; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): 2nd Generation SUs
B: Arm Label: 2nd generation sulfonylureas; Type: N/A; Interventions: Drug: Sulfonylurea | Arm Label: Linagliptin; Type: N/A; Interventions: Drug: Linagliptin | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): 2nd generation sulfonylureas
C: Arm Label: DPP4i; Type: N/A; Interventions: Drug: DPP-4 inhibitor | Arm Label: Empagliflozin; Type: N/A; Interventions: Drug: Empagliflozin | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: DPP-4 inhibitor; Assigned to Arm(s): DPP4i
D: Arm Label: Dapagliflozin; Type: N/A; Interventions: Drug: Dapagliflozin | Arm Label: DPP-4 inhibitor; Type: N/A; Interventions: Drug: DPP-4 inhibitor | Intervention Type: DRUG; Name: Dapagliflozin; Assigned to Arm(s): Dapagliflozin | Intervention Type: DRUG; Name: DPP-4 inhibitor; Assigned to Arm(s): DPP-4 inhibitor

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Replication of the LEADER Diabetes Trial in Healthcare Claims
Brief Summary: Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.


Options:
A: Arm Label: Clopidogrel 75 mg; Type: N/A; Interventions: Drug: Clopidogrel 75mg | Arm Label: Prasugrel 10 mg; Type: N/A; Interventions: Drug: Prasugrel 10mg | Intervention Type: DRUG; Name: Prasugrel 10mg; Assigned to Arm(s): Prasugrel 10 mg | Intervention Type: DRUG; Name: Clopidogrel 75mg; Assigned to Arm(s): Clopidogrel 75 mg
B: Arm Label: Linagliptin; Type: N/A; Interventions: N/A | Arm Label: Glimepiride; Type: N/A; Interventions: N/A
C: Arm Label: DPP-4 inhibitor; Type: N/A; Interventions: Drug: DPP-4 inhibitor | Arm Label: Liraglutide; Type: N/A; Interventions: Drug: Liraglutide | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: DPP-4 inhibitor; Assigned to Arm(s): DPP-4 inhibitor
D: Arm Label: DPP4i; Type: N/A; Interventions: Drug: DPP-4 inhibitor | Arm Label: Empagliflozin; Type: N/A; Interventions: Drug: Empagliflozin | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: DPP-4 inhibitor; Assigned to Arm(s): DPP4i

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Replication of the TECOS Diabetes Trial in Healthcare Claims
Brief Summary: Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.


Options:
A: Arm Label: 2nd Generation SUs; Type: N/A; Interventions: Drug: Sulfonylurea | Arm Label: Sitagliptin; Type: N/A; Interventions: Drug: Sitagliptin | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): 2nd Generation SUs
B: Arm Label: DPP4i; Type: N/A; Interventions: Drug: DPP-4 inhibitor | Arm Label: Empagliflozin; Type: N/A; Interventions: Drug: Empagliflozin | Intervention Type: DRUG; Name: Empagliflozin; Assigned to Arm(s): Empagliflozin | Intervention Type: DRUG; Name: DPP-4 inhibitor; Assigned to Arm(s): DPP4i
C: Arm Label: 2nd generation sulfonylureas; Type: N/A; Interventions: Drug: Sulfonylurea | Arm Label: Linagliptin; Type: N/A; Interventions: Drug: Linagliptin | Intervention Type: DRUG; Name: Linagliptin; Assigned to Arm(s): Linagliptin | Intervention Type: DRUG; Name: Sulfonylurea; Assigned to Arm(s): 2nd generation sulfonylureas
D: Arm Label: DPP4i; Type: N/A; Interventions: Drug: DPP-4 inhibitor | Arm Label: Canagliflozin; Type: N/A; Interventions: Drug: Canagliflozin | Intervention Type: DRUG; Name: Canagliflozin; Assigned to Arm(s): Canagliflozin | Intervention Type: DRUG; Name: DPP-4 inhibitor; Assigned to Arm(s): DPP4i

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Brief Summary: This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 840 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio at approximately 180 sites.


Options:
A: Arm Label: Cabozantinib (XL184); Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib tablets | Arm Label: Everolimus (Afinitor); Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus (Afinitor) tablets | Intervention Type: DRUG; Name: Cabozantinib tablets; Assigned to Arm(s): Cabozantinib (XL184) | Intervention Type: DRUG; Name: Everolimus (Afinitor) tablets; Assigned to Arm(s): Everolimus (Afinitor)
B: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib, Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cabozantinib-matched placebo | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Experimental Arm | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: DRUG; Name: Cabozantinib-matched placebo; Assigned to Arm(s): Control Arm
C: Arm Label: Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Arm B: Sunitinib 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A: Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg, Arm B: Sunitinib 50 mg | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Arm B: Sunitinib 50 mg
D: Arm Label: Lenvatinib; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib | Arm Label: Lenvatinib plus Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib, Lenvatinib plus Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus, Lenvatinib plus Everolimus

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Hybrid Effectiveness-implementation Trial of Go NAPSACC: A Childcare-based Obesity Prevention Program
Brief Summary: This study will compare the effectiveness and cost of Basic and Enhanced delivery models for Go NAPSACC on child care centers' use of evidence-based nutrition and physical activity practices. Technical assistance (TA) coaches from Child Care Aware of Kentucky will lead delivery. Half of the TA coaches will deliver Go NAPSACC using the Basic model and the other half will deliver the program using the Enhanced model. It is hypothesized that the Enhanced model will result in greater use of evidence-based nutrition and physical activity practices and will also be more cost effective.


Options:
A: Arm Label: Program SI! educational intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Program SI! educational intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Program SI! educational intervention; Assigned to Arm(s): Program SI! educational intervention
B: Arm Label: Early Responders to Low Intensity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Intensity | Arm Label: Non-Responders Continue Low Intensity; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low Intensity | Arm Label: Non-Responders Increasing to High Intensity; Type: EXPERIMENTAL; Interventions: Behavioral: Low Intensity, Behavioral: High Intensity | Intervention Type: BEHAVIORAL; Name: Low Intensity; Assigned to Arm(s): Early Responders to Low Intensity, Non-Responders Continue Low Intensity, Non-Responders Increasing to High Intensity | Intervention Type: BEHAVIORAL; Name: High Intensity; Assigned to Arm(s): Non-Responders Increasing to High Intensity
C: Arm Label: Enhanced Go NAPSACC; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Go NAPSACC | Arm Label: Basic Go NAPSACC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Go NAPSACC | Intervention Type: BEHAVIORAL; Name: Enhanced Go NAPSACC; Assigned to Arm(s): Enhanced Go NAPSACC | Intervention Type: BEHAVIORAL; Name: Basic Go NAPSACC; Assigned to Arm(s): Basic Go NAPSACC
D: Arm Label: Train-the-Trainers Arm; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Caregivers- Healthy Children Toolkit | Arm Label: Attention Control Arm; Type: OTHER; Interventions: Behavioral: Safety Curriculum | Intervention Type: BEHAVIORAL; Name: Healthy Caregivers- Healthy Children Toolkit; Assigned to Arm(s): Train-the-Trainers Arm | Intervention Type: BEHAVIORAL; Name: Safety Curriculum; Assigned to Arm(s): Attention Control Arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Hybrid Effectiveness-implementation Trial of Go NAPSACC: A Childcare-based Obesity Prevention Program
Brief Summary: This study will compare the effectiveness and cost of Basic and Enhanced delivery models for Go NAPSACC on child care centers' use of evidence-based nutrition and physical activity practices. Technical assistance (TA) coaches from Child Care Aware of Kentucky will lead delivery. Half of the TA coaches will deliver Go NAPSACC using the Basic model and the other half will deliver the program using the Enhanced model. It is hypothesized that the Enhanced model will result in greater use of evidence-based nutrition and physical activity practices and will also be more cost effective.


Options:
A: Intervention Type: BEHAVIORAL; Name: Physical activity and diet; Assigned to Arm(s): N/A
B: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Arm Label: Email and 4 Home Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Emails and 4 Home Visits | Arm Label: Email and 2 Home Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Emails and 2 home visits | Intervention Type: BEHAVIORAL; Name: Emails and 4 Home Visits; Assigned to Arm(s): Email and 4 Home Visits | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Emails and 2 home visits; Assigned to Arm(s): Email and 2 Home Visits
C: Arm Label: NOURISH-T; Type: EXPERIMENTAL; Interventions: Behavioral: NOURISH-T | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Usual Care | Intervention Type: BEHAVIORAL; Name: NOURISH-T; Assigned to Arm(s): NOURISH-T | Intervention Type: BEHAVIORAL; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care
D: Arm Label: Enhanced Go NAPSACC; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Go NAPSACC | Arm Label: Basic Go NAPSACC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Basic Go NAPSACC | Intervention Type: BEHAVIORAL; Name: Enhanced Go NAPSACC; Assigned to Arm(s): Enhanced Go NAPSACC | Intervention Type: BEHAVIORAL; Name: Basic Go NAPSACC; Assigned to Arm(s): Basic Go NAPSACC

Answer: D